Yesafili (Aflibercept-Jbvf) for AMD

Overview
Yesafili is approved by the U.S. Food and Drug Administration (FDA) for the treatment of neovascular (wet) age-related macular degeneration (AMD), as well as macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Yesafili is also known by its drug name, aflibercept-jbvf.

Yesafili belongs to the category of vascular endothelial growth factor (VEGF) inhibitors. It works by blocking VEGF, a protein that promotes the growth of abnormal blood vessels in the eye, thereby reducing fluid leakage and preventing further vision loss.

How do I take it?
Prescribing information states that Yesafili is administered by intravitreal injection (injection into the eye). The recommended dosing schedule for wet AMD starts with injections every four weeks for the first three months, followed by injections every eight weeks. Dosing schedules and amounts vary from person to person depending on their individual diagnosis. 

Side effects
Common side effects of Yesafili include conjunctival hemorrhage (bleeding under the conjunctiva, a thin membrane that covers the white of the eye), eye pain, cataracts, vitreous detachment (separation of the vitreous gel from the retina), vitreous floaters (small specks or clouds moving in the field of vision), and increased intraocular pressure.

Rare but serious side effects may include endophthalmitis (severe inflammation inside the eye), retinal detachment, retinal vasculitis (inflammation of the retinal blood vessels), and arterial thromboembolic events (blood clots in arteries). 

For more information about this treatment, visit:

Yesafili (Aflibercept-Jbvf) Injection, for Intravitreal Use — U.S. Food and Drug Administration

Yesafili — Drugs.com